title: Randomized trial comparing the efficacy between different types of paclitaxel-eluting stents: the comparison of efficacy between COroflex PLEASe ANd Taxus stent (ECO-PLEASANT) randomized controlled trial.
abstract: OBJECTIVE
  Paclitaxel-eluting stents (PESs) have been shown to inhibit neointimal hyperplasia after percutaneous coronary intervention. Coroflex Please (B Braun, Melsungen, Germany) is a newly developed PES. We compared the clinical and angiographic efficacy of Coroflex Please with Taxus Liberte (Boston Scientific, Natick, MA) in a real-world practice.
  
  
  RESULTS
  We performed a prospective, open-label, randomized, controlled study that enrolled 945 patients undergoing percutaneous coronary interventions in 18 centers in Korea. The primary end point was clinically driven target vessel revascularization at 9 months. The baseline characteristics were mostly similar and comparable between 2 groups. At 9 months, the incidence of clinically driven target vessel revascularization was 14.6% for Coroflex and 6.4% for Taxus, which was significantly different (hazard ratio 2.43, 95% CI 1.50-3.94, noninferiority P value = 1.000). This is well corroborated by the difference of in-stent late loss between 2 stents (0.71 ± 0.64 mm vs 0.52 ± 0.50 mm, P < .001) by 9-month follow-up angiography (n = 415 vs 215). Among secondary clinical end points, stent thrombosis (definite and probable) for 1 year was 2.2% in Coroflex and 1.3% in Taxus (P = .317). Also, myocardial infarction for 9 months was higher in Coroflex group than that in Taxus (4.9% vs 1.6%, P = .012), which was partly contributed by the higher incidence of periprocedural myocardial infarction in Coroflex arm (2.2% vs 0.3%, P = .028).
  
  
  CONCLUSIONS
  Coroflex Please was inferior to Taxus Liberte with regard to clinical and angiographic efficacy.
authors.affiliation: Seoul National University Boramae Medical Center, Seoul, Korea.
authors.forename: Jae-Bin
authors.initials: JB
authors.lastname: Seo
authors.forename: Si-Hyuck
authors.initials: SH
authors.lastname: Kang
authors.forename: Seung-Ho
authors.initials: SH
authors.lastname: Hur
authors.forename: Kyung Woo
authors.initials: KW
authors.lastname: Park
authors.forename: Tae-Jin
authors.initials: TJ
authors.lastname: Youn
authors.forename: Jong-Seon
authors.initials: JS
authors.lastname: Park
authors.forename: Han-Mo
authors.initials: HM
authors.lastname: Yang
authors.forename: Hae-Young
authors.initials: HY
authors.lastname: Lee
authors.forename: Hyun-Jae
authors.initials: HJ
authors.lastname: Kang
authors.forename: Bon-Kwon
authors.initials: BK
authors.lastname: Koo
authors.forename: Jang-Ho
authors.initials: JH
authors.lastname: Bae
authors.forename: Sang-Wook
authors.initials: SW
authors.lastname: Kim
authors.forename: Keon-Woong
authors.initials: KW
authors.lastname: Moon
authors.forename: Jae-Woong
authors.initials: JW
authors.lastname: Choi
authors.forename: Sang-Gon
authors.initials: SG
authors.lastname: Lee
authors.forename: Woo-Young
authors.initials: WY
authors.lastname: Chung
authors.forename: Soo-Joong
authors.initials: SJ
authors.lastname: Kim
authors.forename: Doo-Il
authors.initials: DI
authors.lastname: Kim
authors.forename: Byung-Ok
authors.initials: BO
authors.lastname: Kim
authors.forename: Min-Su
authors.initials: MS
authors.lastname: Hyon
authors.forename: Keum-Soo
authors.initials: KS
authors.lastname: Park
authors.forename: Tae-Joon
authors.initials: TJ
authors.lastname: Cha
authors.forename: Chul-Woong
authors.initials: CW
authors.lastname: Yoo
authors.forename: Hui-Kyung
authors.initials: HK
authors.lastname: Jeon
authors.forename: Hyo-Soo
authors.initials: HS
authors.lastname: Kim
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000601:surgery*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000494:pharmacology*; D011446:Prospective Studies; D011474:Prosthesis Design; D020123:Sirolimus / Q000494:pharmacology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus